Neurelis, Inc. to Participate in the 5th Annual Evercore ISI HealthCONx Conference
SAN DIEGO, CA — November 28, 2022 — Neurelis, Inc., a commercial-stage neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet medical need, today announced that corporate leadership will participate in a fireside chat and one-on-one investor meetings at the 5th […]
NEURELIS SUPPORTS SOFIE’S JOURNEY EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT DISNEYLAND® RESORT
Largest, worldwide epilepsy community gathering will feature a physician presentation on VALTOCO® (diazepam nasal spray) CIV for frequent seizure activity Little Angels Service Dogs’ seizure alert and response puppies-in-training to appear at Neurelis booth and for onstage demonstrations SAN DIEGO, CA — October 31, 2022 — Neurelis is a proud supporter of the 10th Annual […]
NEURELIS RANKED THIRD BEST PLACE TO WORK IN SoCAL 2022
SAN DIEGO, CA — October 24, 2022 — Neurelis, Inc., is pleased to announce it was ranked third among medium-size employers on the Best Places to Work in SoCal 2022 list by Best Companies Group (BCG), a BridgeTower Media Company. This distinction is based on responses from a detailed and comprehensive survey of its employees. […]
NEURELIS PRESENTS NOVEL, INVESTIGATIONAL ANALYSIS OF VALTOCO® (DIAZEPAM NASAL SPRAY) CIV DEMONSTRATING INCREASED TIME BETWEEN SEIZURE CLUSTERS AT THE 51ST CHILD NEUROLOGY SOCIETY ANNUAL MEETING
Two posters highlight findings from a long term safety study of VALTOCO in a pediatric population The first features investigational data indicating a doubling of time between VALTOCO treated seizure clusters across 12 months The second summarizes a sub-analysis showing no long-term safety differences for VALTOCO in patients with Lennox-Gastaut Syndrome and other pediatric epileptic […]
NEURELIS ANNOUNCES PRESENTATION OF ANALYSIS OF TIME BETWEEN SEIZURE CLUSTERS WITH VALTOCO® (DIAZEPAM NASAL SPRAY) CIV AT THE 2022 ANNUAL MEETING OF THE ACADEMY OF MANAGED CARE PHARMACY
Analysis of 12-month, Phase 3 study shows 2-fold increase in time between VALTOCO treated seizure clusters, or SEIzure interVAL (SEIVAL) SAN DIEGO, CA — October 12, 2022 — Neurelis, Inc., a commercial-stage neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet […]
NEURELIS STRENGTHENS LEADERSHIP TO FURTHER ENHANCE GROWING MOMENTUM IN SEIZURE-RESCUE MARKET
Company promotes Brittany Bradrick to Chief Operating Officer (COO) and Chief Financial Officer (CFO) SAN DIEGO, CA — October 6, 2022 — Building on a transformative year of growth and success, Neurelis, Inc., announced today that it promoted former CFO Brittany Bradrick to COO and CFO. Ms. Bradrick’s impact both within Neurelis and among our […]
STUDY PUBLISHED IN EPILEPSIA SHOWS SIGNIFICANT PROLONGATION OF TIME INTERVALS BETWEEN SEIZURE CLUSTERS TREATED WITH NEURELIS’ VALTOCO® (DIAZEPAM NASAL SPRAY) CIV
Novel clinical data highlights the potential for future research into additional benefits of rescue medications in treating individual seizure clusters SAN DIEGO, CA — September 7, 2022 — Neurelis, Inc., announced the recent online publication of a novel data analysis, evaluating the time interval between seizure clusters, or SEIzure interVAL (SEIVAL) in Epilepsia that indicates […]
Neurelis, Inc., Little Angels Service Dogs Present Aug. 25 “Barks ‘n Blues Music & More” Concert to Build Epilepsy Awareness at Local Community Event
SAN DIEGO, CA — August 19, 2022 — Neurelis and Little Angels Service Dogs are proud to present the “Barks ‘n Blues Music & More” concert for epilepsy awareness at the Quartyard, 1301 Market St., San Diego, Thursday, Aug. 25 at 5 p.m. PT. Featured performers include five-time San Diego Music Award winner, Whitney Shay, […]
NEURELIS, INC., NAMED TO LIST OF BEST PLACES TO WORK IN SoCAL 2022
Company culture cultivates passioned innovation and purpose in employees to empower those impacted by epilepsy and other rare disorders SAN DIEGO, CA — August 18, 2022 — Neurelis, Inc., is pleased to announce it has been named one of the Best Places to Work in SoCal 2022 by Best Companies Group (BCG), a BridgeTower Media […]
NEURELIS STUDY PUBLISHED IN EPILEPSIA, A WORLD-CLASS JOURNAL DEDICATED TO EPILEPSY
SAN DIEGO, CA – June 9, 2022 — Neurelis, Inc., announced the publication of a study recently available online in the peer-reviewed, scientific journal Epilepsia. Epilepsia is the world’s leading journal of original scientific research on multiple aspects of epilepsy. Epilepsia publishes reviews, opinion pieces, and guidelines that foster understanding and aim to improve the […]